Brainstorm Cell Therapeutics (NASDAQ:BCLI) Downgraded by StockNews.com to “Sell”

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ:BCLI traded down $0.14 during mid-day trading on Wednesday, reaching $2.09. The stock had a trading volume of 63,331 shares, compared to its average volume of 55,926. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89. The business has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $3.32. The firm has a market capitalization of $11.92 million, a price-to-earnings ratio of -0.44 and a beta of 0.29.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.